Kornimate/medical-research-clean huggingface dataset:
spinal kinematics variability

Conditions: Chronic Low Back Pain

Summary: this study will test the within and between day variability of spinal kinematics and trunk muscle activity in healthy subjects and chronic low back pain patients during various daily-life activities.

this study will test the within and between day variability of spinal kinematics and trunk muscle activity in healthy subjects and chronic low back pain patients during various daily-life activities. participants will come twice to the motion laboratory. during the first session, participants will first perform different functional activities (v1), such as sit-to-stand, gait, lifting tasks, stepping up. their spinal kinematics will be measured with a camera-based system (vicon) using a multi-segment spinal model and trunk muscles activity will be recorded with surface electromyography. after a break, participants will have to perform all the functional activities a second time (v2). these two measures (v1 and v2) will be used to determine the within day variability of spinal kinematics. finally, all participants will come one week later (v3) to repeat all the measurements to determine the between day variability.

Eligibility criteria:
inclusion criteria: * sufficient french level to understand the instructions for the tests, the information sheet, the consent form and the questionnaires * all chronic low back pain patients should present with non-specific low back pain (pain from lower ribs to gluteal folds) for more than 3 months. exclusion criteria: * pregnancy * body mass index (bmi) that is above 32 * patients should not have any sign of specific low back pain such as the presence of infection, rheumatological or neurological diseases, spinal fractures, any known important spinal deformities, previous back surgery that limits spinal mobility, tumours * high level of pain at the time of experiment that prevents repeated movements (severity and irritability) * other concomitant pain or condition that could compromise the evaluation of spinal kinematics.
respiratory training in individuals with ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Exercise Training; Diaphragm; Mobility

Summary: this study was designed to investigate and compare the effects of standard diaphragmatic breathing and physiotherapy exercises versus 360-degree expandable diaphragmatic breathing and physiotherapy exercises on respiratory functions, respiratory muscle strength, clinical course of the disease (such as thoracic mobility, flexibility), and functional status in individuals with ankylosing spondylitis (as).

one of the primary problems in ankylosing spondylitis (as) is decreased thoracic expansion. for this reason, breathing exercises, especially thorax expansion, should be included. moreover, according to pascal\&#39;s principle, the pressure applied to a closed fluid must be transmitted to every part of the fluid and to the walls of the space in which it is located, without decreasing (13). for this reason, it is thought that the disrupted breathing pattern cannot be adequately corrected by standard diaphragm exercises, in which the patient\&#39;s hand is placed on the abdomen and the anterior abdominal wall is pushed forward/outward, and the diaphragm descent to the caudal level during inspiration with 360-degree expansion of the thoraco-abdominal cavity may not be sufficient (14). the aims of this study are as follows: 1. to examine and compare the effects of standard diaphragmatic breathing and physiotherapy exercises and 360-degree expanded diaphragm exercises and physiotherapy exercises on respiratory function in individuals with as. 2. to examine and compare the effects of standard diaphragmatic breathing and physiotherapy exercises, 360-degree expanded diaphragm exercises and physiotherapy exercises on inspiratory and expiratory muscle strength in individuals with as. 3. to examine and compare the effects of standard diaphragmatic breathing and physiotherapy exercises, 360-degree expanded diaphragm exercises and physiotherapy exercises on spinal mobility and the clinical course of the disease in individuals with as.

Eligibility criteria:
inclusion criteria: * age between 20-60 years * diagnosis according to the 1988 modified new york criteria * voluntary participation * basdai score of 3 or 4 * no mental problems that could hinder cooperation and understanding exclusion criteria: * presence of a neurological disease * other respiratory system diseases that could affect chest expansion (copd, asthma, etc.) * regular exercise within the last 3 months additionally, individuals who miss four consecutive exercise sessions or require a change in treatment will be excluded from the study.

Keywords: ankylosing spondylitis breathing mobility functional capacity physiotherapy
the predictive value of cytokines on response to preoperative chemoradiotherapy in patients with rectal cancer

Conditions: Rectal Cancer

Summary: rationale and background: predictive factors are needed to discriminate chemoradiotherapy responders from non-responders and to individualize the treatment regime. various cytokines play a role in processes affecting tumour growth and metastasis. furthermore, cytokines might influence treatment response. various cytokines are abnormally expressed in colorectal cancer patients, are associated with colorectal cancer or determine response to chemoradiotherapy. therefore the investigators want to investigate whether levels of circulating cytokines could predict response to preoperative chemoradiotherapy in patients with rectal cancer. hypothesis: the investigators hypothesis is that the varying levels of circulating cytokines in the blood of rectal cancer patients may predict the response to preoperative chemoradiotherapy. study design: this study is an explorative clinical pilot study in which the investigators will collect 4 ml of blood from a selection of rectal cancer patients during a regular venipuncture before, during and after preoperative chemoradiotherapy and before and after surgery. cytokines will be measured in blood plasma and in tumour and healthy tissue from the resection specimen using multiplex immunoassays. plasma cytokine measurements will be linked to pathological response to identify which cytokines and corresponding levels can predict response to preoperative chemoradiotherapy for patients with locally advanced rectal cancer. furthermore, blood plasma cytokine measurements before and after surgery will be compared to evaluate the effect of tumour resection on the immune response. in addition, preoperative blood plasma cytokine levels will be compared with cytokine levels in normal and tumour tissue to test whether circulating cytokine levels are representative for tissue cytokine levels. study population: thirty patients (≥18 years) with locally advanced rectal adenocarcinoma eligible for preoperative chemoradiotherapy (oral capecitabine and 45-50 gray (gy) in total; fractions of 1.8-2 gy) and surgery. country of recruitment: the netherlands


Eligibility criteria:
inclusion criteria: * pathohistological diagnosis of locally advanced rectal adenocarcinoma (\<15 cm from the anal verge) * eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 gy in total; fractions of 1.8-2 gy) and surgery (stage 2 or 3 rectal cancer) * planned to undergo a venipuncture for a regular blood collection during preoperative chemoradiotherapy, before, and after surgery * written informed consent * age ≥18 exclusion criteria: * age \<18 * serious adverse events during preoperative chemoradiotherapy * use of corticosteroids and/or immunosuppressive drugs during or 1 month prior to the study * other malignancies in medical history * previous pelvic radiotherapy and/or chemotherapy * confirmed bacterial or viral infection during the study or 3 months prior to the study

Keywords: cytokines predictive value preoperative chemoradiotherapy rectal cancer
a trial of camrelizumab in combination with nab-paclitaxel and famitinib as a first line treatment in patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast cancer(future-c-plus)

Conditions: Triple-Negative Breast Cancer

Summary: the study is being conducted to evaluate the efficacy, safety of camrelizumab in combination with nab-paclitaxel and famitinib in patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast cancer..


Eligibility criteria:
inclusion criteria: * ecog performance status of 0-1 * expected lifetime of not less than three months * metastatic or locally advanced, histologically documented tnbc (absence of her2, er, and pr expression) * cancer stage: recurrent or metastatic breast cancer; local recurrence be confirmed by the researchers could not be radical resection. * adequate hematologic and end-organ function, laboratory test results. * measurable disease according to response evaluation criteria in solid tumors v1.1 (recist v1.1) * patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer exclusion criteria: * previous received anti-vegfr small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, sunitinib, regorafenib, etc.) for treatment of the patients . * a history of bleeding, any serious bleeding events. * important blood vessels around tumors has been infringed and high risk of bleeding. * coagulant function abnormality * artery/venous thromboembolism event * history of autoimmune disease * positive test for human immunodeficiency virus * active hepatitis b or hepatitis c * uncontrolled pleural effusion and ascites * known central nervous system (cns) disease. * long-term unhealing wound or incomplete healing of fracture * urine protein ≥2+ and 24h urine protein quantitative \> 1 g. * pregnancy or lactation. * thyroid dysfunction. * peripheral neuropathy grade ≥2. * people with high blood pressure; * a history of unstable angina; * new diagnosis of angina pectoris. * myocardial infarction incident ; * arrhythmia for long-term use of anti-arrhythmic drugs and new york heart association class ii or higher cardiac insufficiency
evaluation of the effect of a physical activity recovery stay

Conditions: Children With Cerebral Palsy; Children With Cancer

Summary: a who study in 2020 revealed that 81% of adolescents (aged 11-17) do not respect the recommendation of one hour of moderate physical activity per day. in the context of disability, many factors impose limits on physical activity. while the pathology itself induces limitations and restrictions (prolonged sitting time, assisted movement, etc.), organizational constraints also apply to both children and parents, who have to divide their time between work, school and therapeutic care, which is sometimes numerous and varied over the course of a single week. these limitations generate stress and fatigue, and prolonged sedentary periods lead children with chronic illnesses, rare diseases or disabilities into a process of physical deconditioning. the accumulation of sedentary time is detrimental to cardiovascular and metabolic health. to combat this deconditioning, the 2008 national physical activity and sport plan (pnaps) sets out the main guidelines for treatment and implementation. the plan explains that "for patients with chronic illnesses, rare diseases or disabilities, the aim is to encourage care and guidance towards adapted physical activity (apa). the attending physician will be able to identify local therapeutic education programs, rehabilitation services and "sport-santé" offers, to improve access for these patients to supervised local programs". in addition, the plan suggests "developing apa programs in healthcare establishments to enable people with chronic illnesses, rare diseases or disabilities to access health education incorporating practical sessions". in line with this plan, an exercise reconditioning program has been set up at our facility. this three-month stay includes children with a variety of pathologies, but with a common feature of physical deconditioning.


Eligibility criteria:
inclusion criteria: * children with a pathology (chronic disease, rare disease or disability) in a state of deconditioning to exercise * taken in charge at the cmpre for a stay to resume physical activity exclusion criteria: * age under 8 and over 18 * patients undergoing rehabilitation during the stay * patients with a significant change in their therapeutic management during the stay * significant cognitive impairment preventing comprehension of instructions * significant club or leisure sports activity (3x/week) * electric wheelchair * non-compliance with stay (5 ½ days missed out of total stay) * participation in another study during the return-to-physical-activity stay
autologous bone marrow mononuclear cell implantation for moderate to severe peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study is to evaluate the efficacy of dual intramuscular and intra-arterial autologous bone marrow mononuclear cell implantation for the treatment of patients with moderate to severe peripheral arterial disease in whom amputation was considered the only viable treatment option. study hypothesis: patients with moderate to severe peripheral arterial disease who receive intramuscular and intra-arterial stem cell injections will have improved ankle brachial index (abi) measurements; relief of rest pain; ulcer healing, if applicable; and absence of major limb amputations.


Eligibility criteria:
inclusion criteria: * patients at least 18 years of age. * patients with moderate or severe limb-threatening pad, defined as ankle brachial indices (abi) less than 0.7 or presence of non-healing ischemic ulcers with stenosis or occlusion of two of the following lower extremity arteries: anterior tibial, posterior tibial, and peroneal. * patients with conditions that preclude recommendation of traditional endovascular or open bypass treatments. exclusion criteria: * patients younger than 18 years of age. * patients who are eligible to undergo traditional endovascular or open bypass for the treatment of pad. * female patients who are or may be pregnant. * patients who are prisoners. * patients with mental retardation or are unable to consent for participation independently.

Keywords: bone marrow transplantation ischemia neoangiogenesis peripheral arterial disease stem cell therapy
a study to compare iberdomide maintenance versus lenalidomide maintenance therapy following autologous stem cell transplant in participants with newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (asct) in participants with newly diagnosed multiple myeloma (ndmm).


Eligibility criteria:
inclusion criteria * confirmed diagnosis of symptomatic multiple myeloma (mm). * eastern cooperative oncology group performance status (ecog) score of 0, 1, or 2. * received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (pi) and immunomodulatory (imid) \[eg, bortezomib thalidomide and dexamethasone (vtd), lenalidomide, bortezomib and dexamethasone (rvd)\] with or without a cd38 monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[d-vtd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[d-vrd\]), or vcd / daratumumab + bortezomib/cyclophosphamide/dexamethasone \[d-vcd\], and followed by a single or tandem autologous stem cell transplantation (asct). post-stem cell transplant consolidation is permitted. * participants within 12 months (single transplant) or 15 months (tandem transplant) from initiation of induction therapy who achieved at least a partial response (pr) after autologous stem cell transplantation (asct) with or without consolidation, according to international myeloma working group (imwg 2016) criteria. exclusion criteria * progressive disease or clinical relapse (as defined by imwg response criteria) following asct with or without consolidation or is not responsive to primary therapy. * smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma. * known central nervous system/meningeal involvement of mm. * prior history of malignancies, other than mm, unless the participant has been free of the disease for ≥ 5 years. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: multiple myeloma iberdomide cc-220 lenalidomide mm ndmm maintenance autologous stem cell transplant asct celmod cereblon modulators
outcomes after esophageal cancer surgery

Conditions: Esophageal Neoplasm; Esophageal Disease

Summary: background * esophageal carcinoma is the sixth leading cause of cancer -related mortality and the eighth most common cancer worldwide * the incidence is increasing rapidly * the overall 5-year survival ranges from 15% to 25% in the literature and poor outcomes are related to diagnosis at advanced stages. * surgery used to be the cornerstone of treatment of resectable esophageal cancer, but treatment of esophageal carcinoma remains challenging and need to be considered through a multimodal approach. however the modalities and the impact of this multimodal approach at a national level are unknown primary objective: to identify predictors of recurrence after esophageal cancer surgery secondary objectives : * 5-year recurrence free survival * 5-year overall survival * predictors of postoperative mortality and morbidity after surgery * impact of pcr on recurrence and survival * impact of neoadjuvant treatments on recurrence and survival * impact of patient preconditioning (such as nutritional support, esophageal prosthesis, mini-invasive approach...) on outcomes methodology : european french-speaking retrospective multicentric study inclusion criteria: all consecutive patients operated on, for a histologically proven carcinoma of the esophagus, the oesophago-gastric junction (siewert type i and ii), in surgical investigator centers between january 2000 and december 2010 exclusion criteria: siewert iii type carcinoma of the oesophago-gastric junction , non surgical treatment of esophageal carcinoma planned study period: the data will be collected over a 11-year period from january 2000 to december 2010. follow up will be ascertained in may 2013.

patients with an esophageal or junctional carcinoma (including siewert type i and ii) with surgical resection of the primary tumor inclusion date will be date of surgery all patients will be followed during 5 years after surgery or time of death

Eligibility criteria:
inclusion criteria: * all consecutive patients operated on for a cancer of the esophagus , a siewert i or ii cancer of the esopgago-gastric junction in surgical oncology investigator centers * surgery performed between 1st january 2000 and 31 december 2010 exclusion criteria: * siewert iii cancer of the oesophago-gastric junction * non surgical treatment of the esophageal cancer * benign lesion

Keywords: esophageal neoplasm esophagus surgery outcome assessment
phase i study of radiolabeled otsa101-dtpa in patients with relapsed or refractory synovial sarcoma

Conditions: Relapsed or Refractory Synovial Sarcoma

Summary: the purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of otsa101-dtpa-111in and to evaluate the safety of intravenous administration of otsa101-dtpa-90y.


Eligibility criteria:
inclusion criteria: 1. patients with a documented relapsed or refractory synovial sarcoma after standard chemotherapy 2. patients ≥18 years of age at the time of obtaining informed consent 3. patients with an eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 4. patients with measurable lesion 5. patients not received any anti-malignancy agent or specified surgical intervention within 28 days or specified radiotherapy within 14 days prior to study registration. 6. patients without any clinically significant laboratory abnormality. 7. patients with adequate heart function as measured by echocardiography or multiple gated acquisition scan (muga). 8. patients with adequate pulmonary function as measured by pulmonary function tests. 9. patients who are either not of childbearing potential or who agree to use a contraception method during the study and for 12 months after the last dose of study drug 10. patients must be able to understand and be willing to sign a written informed consent exclusion criteria: 1. patients with documented concurrent malignancy. 2. patients with brain metastasis with clinical symptoms. 3. patients with any infection requiring systemic treatment. 4. patients with lung inflammation or pulmonary fibrosis. 5. patients with a known history of hypersensitivities to antibody agents or serum albumin agents. 6. patients with a known history of autoimmune diseases. 7. patients with myocardial infarction (mi) within 6 months prior to study registration. 8. patients with uncontrolled diseases. 9. patients with any disease requiring continuous systemic administration of steroids or immunosuppressants. 10. patients with evidence of active hbv, hcv or hiv infection. 11. pregnant or breastfeeding female patients, or female patients with suspected pregnancy. 12. patients who are participating any other investigational treatments during the study. 13. patients with psychiatric disorders and is considered to have difficulty to study participation.
effect of pre-operative forearm exercises on arterial venous fistula maturation and blood flow

Conditions: End Stage Renal Disease; Arteriovenous Fistula

Summary: this study will investigate the effect of pre-operative exercise on hemodynamics in the fistula artery and vein, pre and post arteriovenous fistula formation as well as the suitability of cannulation of arteriovenous fistula at 12 weeks post surgery. this is a randomised control study with 20 patients each in the control arm (group a) or the exercise arm (group b). the subjects will be randomised into 1:1 into one of the two groups. the patients will have an ultrasound doppler vein mapping done prior surgery and the necessary follow up visits.

the incident and prevalent population on renal replacement therapy for end stage renal disease (esrd) is steadily increasing in singapore as well as other countries worldwide. around 85 - 90% of the prevalent dialysis population is on hemodialysis and arteriovenous fistula (avf). avf is considered the gold standard for safe and effective vascular access for hemodialysis treatment due to its low rates of complication. however, primary failure rate of avfs remain high at around 20 - 25% depending on the site of the surgery, contributed by several factors including the diameter of the artery and the vein used for avf formation. if pre-operative exercise improves the hemodynamics of the avf and aids the maturation rate in our study, it can be incorporated into clinical guidelines to reduce the primary failure rate of avf. even though, there is sufficient evidence to support the beneficial role of the forearm exercises on fistula blood flow and maturation, there are no studies looking at the effects of pre-operative exercise on avf maturation. our study is aiming to fulfil this gap in knowledge.

Eligibility criteria:
inclusion criteria: * age \>=21 to \<= 90. * chronic kidney failure patients with estimated glomerular filtration rate (egfr) less than 20mls/min. * haemodialysis is chosen as their modality of renal replacement therapy. exclusion criteria: * potential fistula vein diameter \<= 3mm (with application of tornique) on initial vein mapping. * known left ventricular ejection fraction of less than 20% on echo diagram. * previous stroke effecting the avf arm. * calcified brachial or radial arteries and/or duplex evidence of stenosis of \>= 50%

Keywords: arteriovenous fistula avf maturation pre operative exercise